Severe Disease

In new guidance, the Infectious Diseases Society of America suggested that immunocompromised patients take the monoclonal antibody pemivibart as pre-exposure prophylaxis to prevent severe COVID-19.

The severity of a SARS-CoV-2 reinfection is likely to be similar to the severity of a patient’s initial infection, researchers found.

The latest COVID-19 vaccines reduce the risk for hospitalization or visits to an ED or urgent care by around 50%, according to interim data published in MMWR.

Higher physical activity levels before the COVID-19 pandemic were associated with lower odds of developing and being hospitalized for COVID-19 in older adults, according to a recent study.

The updated COVID-19 vaccines were approximately 54% effective against symptomatic SARS-CoV-2 infection and offered protection against JN.1 and XBB viral lineages, according to early estimates published Thursday by the CDC.

Phase 2 trial results found lutikizumab was efficacious in treating hidradenitis suppurativa in patients who had previously failed anti-tumor necrosis factor therapy, AbbVie announced in a press release.

Convolutional neural networks may be able to detect hidradenitis suppurativa-affected skin and classify disease severity, according to a study.

The risk for severe disease or death among U.S. adults with COVID-19 was highest for unvaccinated inpatients and those infected with the delta variant, according to a recent study published in Clinical Infectious Diseases.

A final analysis showed that Novavax’s COVID-19 vaccine was 96.4% efficacious against mild, moderate or severe disease caused by wild SARS-CoV-2 in a phase 3 trial in the United Kingdom, the company said.

Researchers at a U.K. hospital said they found no evidence that children hospitalized recently with COVID-19 were sicker than children hospitalized with the disease last year, suggesting the B.1.1.7 variant does not make kids more ill.